Shortwave Life Sciences (AQSE:PSY) Change In Receivables : £0.00 Mil (TTM As of . 20)

View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Change In Receivables?

Shortwave Life Sciences's change in receivables for the quarter that ended in . 20 was £0.00 Mil. It means Shortwave Life Sciences's Accounts Receivable stayed the same from . 20 to . 20 .

Shortwave Life Sciences's change in receivables for the fiscal year that ended in . 20 was £0.00 Mil. It means Shortwave Life Sciences's Accounts Receivable stayed the same from . 20 to . 20 .

Shortwave Life Sciences's Accounts Receivable for the quarter that ended in . 20 was £0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shortwave Life Sciences's liquidation value for the six months ended in . 20 was £0.00 Mil.

Shortwave Life Sciences Change In Receivables Historical Data

The historical data trend for Shortwave Life Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Change In Receivables Chart

Shortwave Life Sciences Annual Data

Trend

Change In Receivables

Shortwave Life Sciences Semi-Annual Data

Change In Receivables

Shortwave Life Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in . 20 was £0.00 Mil.

Shortwave Life Sciences (AQSE:PSY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shortwave Life Sciences's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Shortwave Life Sciences's accounts receivable are only considered to be worth 75% of book value:

Shortwave Life Sciences's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Shortwave Life Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shortwave Life Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shortwave Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.shortwavelifesciences.com

Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.